



COURSE DIRECTORS
PROF. SIBEL ALPER, ISTANBUL, TURKEY
PROF. CLAU GARBE, TUEBINGEN, GERMANY

SECOND EUROPEAN SCHOOL OF DERMATO- ONCOLOGY, ORGANIZED BY EADO: FUNDAMENTALS OF CUTANEOUS ONCOLOGY

WWW.DERMATO-ONCOLOGY2014.ORG

**PRELIMINARY
PROGRAM**

**ISTANBUL, TURKEY
JANUARY 16TH-18TH, 2014
POINT HOTEL TAKSIM**



Content

EADO European School of Dermato-Oncology	2
Target Audience	2
Educational Objectives	2
Course Organization	3
Program Overview	4
Program	6
Thursday, January 16 th , 2014	6
Friday, January 17 th , 2014	7
Saturday, January 18 th , 2014	9
EADO Dermato-Oncology Committee	11
Course Faculty	11
General Information	12
Registration Form	15

EADO European School of Dermato-Oncology

The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website (www.eado.org). The EADO initiates for the second time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease. It is intended to organize this course every year in different countries.

Target Audience

This 2,5-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

The maximum number of delegates is 100. In order to make the course available throughout Europe, places will be made available on a first come first served basis to all applicants.

Educational Objectives

The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of loco-regional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge:

1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy.
2. The indications, risks and benefits and strategies for mole screening.
3. Diagnosis of skin cancer: how to break bad news.
4. The indications and methods for genetic diagnosis and genetic counseling of skin cancer patients.
5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.

6. The value of imaging and biomarkers for the detection of metastases and disease staging.
7. Adjuvant treatment of skin cancer: radiotherapy; immunotherapy; chemotherapy.
8. New systemic treatments for stage IV melanoma: targeted agents and immunotherapeutics.
9. New treatment options of advanced basal cell carcinoma.
10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma.
11. The characteristics of mucosal and uveal melanomas and their treatment options.
12. Options for topical treatment of epithelial skin cancers.
13. The current classification of cutaneous lymphoma; staging and treatment options for different subtypes of cutaneous lymphoma.
14. Clinical trials in skin cancer: an update.
15. The indications and strategies for supportive treatments including best supportive care.

Course Organization

The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained.

The main part of the course consists of 8 interactive sessions, each with no more than 25 attendants. Every participant takes part in each of these sessions which mainly comprise case-based discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made.



Sibel Alper, MD & Claus Garbe, MD
Course Directors

Program Overview

A commercial exhibition will be held on all days close to the meeting rooms.

	8:00	9:00	10:00	11:00	12:00
Thursday January 16th, 2014					
Group I					
Group II					
Group III					
Group IV					
Friday January 17th, 2014					
Group I	LECTURE 3 <i>V. del Marmol</i>	LECTURE 4 <i>I. Longo</i>	LECTURE 5 <i>C. Garbe</i>	Break	COURSE C <i>A. Stratigos</i>
Group II					COURSE D <i>R.Y. Anadolu</i>
Group III					COURSE A <i>K. Peris</i>
Group IV					COURSE B <i>C. Garbe</i>
				Break	COURSE D <i>R.Y. Anadolu</i>
			COURSE A <i>K. Peris</i>		COURSE A <i>K. Peris</i>
			COURSE B <i>C. Garbe</i>		COURSE B <i>C. Garbe</i>
					COURSE C <i>A. Stratigos</i>
Saturday January 18th, 2014					
Group I	COURSE G <i>C. Lebbé</i>	LECTURE 8 <i>C. Garbe</i>	LECTURE 9 <i>A. Hauschild</i>	Break	COURSE H <i>C. Robert</i>
Group II	COURSE H <i>C. Robert</i>				COURSE E <i>J. Grob</i>
Group III	COURSE E <i>J. Grob</i>				COURSE F <i>A. Hauschild</i>
Group IV	COURSE F <i>A. Hauschild</i>				COURSE G <i>C. Lebbé</i>
				Break	LECTURE 10 <i>J. Oldh</i>
					LECTURE 11 <i>J. Becker</i>
					LECTURE 12 <i>N. Iiter</i>

13:00	14:00	15:00	16:00	17:00	18:00
LECTURE 13 <i>R. Dummer</i>	Lunch	LECTURE 6 <i>H. Pehamberger</i>	LECTURE 7 <i>E. Stockfleth</i>	Break	LECTURE 1 <i>J. Malvey</i>
Lunch	Break	LECTURE 6 <i>J. Grob</i>	LECTURE 7 <i>A. Hauschild</i>	LECTURE 8 <i>C. Lebbé</i>	LECTURE 9 <i>C. Robert</i>
LECTURE 16 <i>A. Hauschild</i>	LECTURE 17 <i>C. Lebbé</i>	LECTURE 18 <i>C. Robert</i>	LECTURE 19 <i>J. Grob</i>	LECTURE 20 <i>A. Hauschild</i>	LECTURE 21 <i>C. Lebbé</i>
LECTURE 28 <i>A. Hauschild</i>	LECTURE 29 <i>C. Lebbé</i>	LECTURE 30 <i>C. Robert</i>	LECTURE 31 <i>J. Grob</i>	LECTURE 32 <i>A. Hauschild</i>	LECTURE 33 <i>C. Lebbé</i>
LECTURE 40 <i>A. Hauschild</i>	LECTURE 41 <i>C. Lebbé</i>	LECTURE 42 <i>C. Robert</i>	LECTURE 43 <i>J. Grob</i>	LECTURE 44 <i>A. Hauschild</i>	LECTURE 45 <i>C. Lebbé</i>
LECTURE 52 <i>A. Hauschild</i>	LECTURE 53 <i>C. Lebbé</i>	LECTURE 54 <i>C. Robert</i>	LECTURE 55 <i>J. Grob</i>	LECTURE 56 <i>A. Hauschild</i>	LECTURE 57 <i>C. Lebbé</i>
LECTURE 64 <i>A. Hauschild</i>	LECTURE 65 <i>C. Lebbé</i>	LECTURE 66 <i>C. Robert</i>	LECTURE 67 <i>J. Grob</i>	LECTURE 68 <i>A. Hauschild</i>	LECTURE 69 <i>C. Lebbé</i>
LECTURE 76 <i>A. Hauschild</i>	LECTURE 77 <i>C. Lebbé</i>	LECTURE 78 <i>C. Robert</i>	LECTURE 79 <i>J. Grob</i>	LECTURE 80 <i>A. Hauschild</i>	LECTURE 81 <i>C. Lebbé</i>
LECTURE 88 <i>A. Hauschild</i>	LECTURE 89 <i>C. Lebbé</i>	LECTURE 90 <i>C. Robert</i>	LECTURE 91 <i>J. Grob</i>	LECTURE 92 <i>A. Hauschild</i>	LECTURE 93 <i>C. Lebbé</i>
LECTURE 100 <i>A. Hauschild</i>	LECTURE 101 <i>C. Lebbé</i>	LECTURE 102 <i>C. Robert</i>	LECTURE 103 <i>J. Grob</i>	LECTURE 104 <i>A. Hauschild</i>	LECTURE 105 <i>C. Lebbé</i>
LECTURE 112 <i>A. Hauschild</i>	LECTURE 113 <i>C. Lebbé</i>	LECTURE 114 <i>C. Robert</i>	LECTURE 115 <i>J. Grob</i>	LECTURE 116 <i>A. Hauschild</i>	LECTURE 117 <i>C. Lebbé</i>
LECTURE 124 <i>A. Hauschild</i>	LECTURE 125 <i>C. Lebbé</i>	LECTURE 126 <i>C. Robert</i>	LECTURE 127 <i>J. Grob</i>	LECTURE 128 <i>A. Hauschild</i>	LECTURE 129 <i>C. Lebbé</i>
LECTURE 136 <i>A. Hauschild</i>	LECTURE 137 <i>C. Lebbé</i>	LECTURE 138 <i>C. Robert</i>	LECTURE 139 <i>J. Grob</i>	LECTURE 140 <i>A. Hauschild</i>	LECTURE 141 <i>C. Lebbé</i>
LECTURE 148 <i>A. Hauschild</i>	LECTURE 149 <i>C. Lebbé</i>	LECTURE 150 <i>C. Robert</i>	LECTURE 151 <i>J. Grob</i>	LECTURE 152 <i>A. Hauschild</i>	LECTURE 153 <i>C. Lebbé</i>
LECTURE 160 <i>A. Hauschild</i>	LECTURE 161 <i>C. Lebbé</i>	LECTURE 162 <i>C. Robert</i>	LECTURE 163 <i>J. Grob</i>	LECTURE 164 <i>A. Hauschild</i>	LECTURE 165 <i>C. Lebbé</i>
LECTURE 172 <i>A. Hauschild</i>	LECTURE 173 <i>C. Lebbé</i>	LECTURE 174 <i>C. Robert</i>	LECTURE 175 <i>J. Grob</i>	LECTURE 176 <i>A. Hauschild</i>	LECTURE 177 <i>C. Lebbé</i>
LECTURE 184 <i>A. Hauschild</i>	LECTURE 185 <i>C. Lebbé</i>	LECTURE 186 <i>C. Robert</i>	LECTURE 187 <i>J. Grob</i>	LECTURE 188 <i>A. Hauschild</i>	LECTURE 189 <i>C. Lebbé</i>
LECTURE 196 <i>A. Hauschild</i>	LECTURE 197 <i>C. Lebbé</i>	LECTURE 198 <i>C. Robert</i>	LECTURE 199 <i>J. Grob</i>	LECTURE 200 <i>A. Hauschild</i>	LECTURE 201 <i>C. Lebbé</i>
LECTURE 208 <i>A. Hauschild</i>	LECTURE 209 <i>C. Lebbé</i>	LECTURE 210 <i>C. Robert</i>	LECTURE 211 <i>J. Grob</i>	LECTURE 212 <i>A. Hauschild</i>	LECTURE 213 <i>C. Lebbé</i>
LECTURE 220 <i>A. Hauschild</i>	LECTURE 221 <i>C. Lebbé</i>	LECTURE 222 <i>C. Robert</i>	LECTURE 223 <i>J. Grob</i>	LECTURE 224 <i>A. Hauschild</i>	LECTURE 225 <i>C. Lebbé</i>
LECTURE 232 <i>A. Hauschild</i>	LECTURE 233 <i>C. Lebbé</i>	LECTURE 234 <i>C. Robert</i>	LECTURE 235 <i>J. Grob</i>	LECTURE 236 <i>A. Hauschild</i>	LECTURE 237 <i>C. Lebbé</i>
LECTURE 244 <i>A. Hauschild</i>	LECTURE 245 <i>C. Lebbé</i>	LECTURE 246 <i>C. Robert</i>	LECTURE 247 <i>J. Grob</i>	LECTURE 248 <i>A. Hauschild</i>	LECTURE 249 <i>C. Lebbé</i>
LECTURE 256 <i>A. Hauschild</i>	LECTURE 257 <i>C. Lebbé</i>	LECTURE 258 <i>C. Robert</i>	LECTURE 259 <i>J. Grob</i>	LECTURE 260 <i>A. Hauschild</i>	LECTURE 261 <i>C. Lebbé</i>
LECTURE 268 <i>A. Hauschild</i>	LECTURE 269 <i>C. Lebbé</i>	LECTURE 270 <i>C. Robert</i>	LECTURE 271 <i>J. Grob</i>	LECTURE 272 <i>A. Hauschild</i>	LECTURE 273 <i>C. Lebbé</i>
LECTURE 280 <i>A. Hauschild</i>	LECTURE 281 <i>C. Lebbé</i>	LECTURE 282 <i>C. Robert</i>	LECTURE 283 <i>J. Grob</i>	LECTURE 284 <i>A. Hauschild</i>	LECTURE 285 <i>C. Lebbé</i>
LECTURE 292 <i>A. Hauschild</i>	LECTURE 293 <i>C. Lebbé</i>	LECTURE 294 <i>C. Robert</i>	LECTURE 295 <i>J. Grob</i>	LECTURE 296 <i>A. Hauschild</i>	LECTURE 297 <i>C. Lebbé</i>
LECTURE 304 <i>A. Hauschild</i>	LECTURE 305 <i>C. Lebbé</i>	LECTURE 306 <i>C. Robert</i>	LECTURE 307 <i>J. Grob</i>	LECTURE 308 <i>A. Hauschild</i>	LECTURE 309 <i>C. Lebbé</i>
LECTURE 316 <i>A. Hauschild</i>	LECTURE 317 <i>C. Lebbé</i>	LECTURE 318 <i>C. Robert</i>	LECTURE 319 <i>J. Grob</i>	LECTURE 320 <i>A. Hauschild</i>	LECTURE 321 <i>C. Lebbé</i>
LECTURE 328 <i>A. Hauschild</i>	LECTURE 329 <i>C. Lebbé</i>	LECTURE 330 <i>C. Robert</i>	LECTURE 331 <i>J. Grob</i>	LECTURE 332 <i>A. Hauschild</i>	LECTURE 333 <i>C. Lebbé</i>
LECTURE 340 <i>A. Hauschild</i>	LECTURE 341 <i>C. Lebbé</i>	LECTURE 342 <i>C. Robert</i>	LECTURE 343 <i>J. Grob</i>	LECTURE 344 <i>A. Hauschild</i>	LECTURE 345 <i>C. Lebbé</i>
LECTURE 352 <i>A. Hauschild</i>	LECTURE 353 <i>C. Lebbé</i>	LECTURE 354 <i>C. Robert</i>	LECTURE 355 <i>J. Grob</i>	LECTURE 356 <i>A. Hauschild</i>	LECTURE 357 <i>C. Lebbé</i>
LECTURE 364 <i>A. Hauschild</i>	LECTURE 365 <i>C. Lebbé</i>	LECTURE 366 <i>C. Robert</i>	LECTURE 367 <i>J. Grob</i>	LECTURE 368 <i>A. Hauschild</i>	LECTURE 369 <i>C. Lebbé</i>
LECTURE 376 <i>A. Hauschild</i>	LECTURE 377 <i>C. Lebbé</i>	LECTURE 378 <i>C. Robert</i>	LECTURE 379 <i>J. Grob</i>	LECTURE 380 <i>A. Hauschild</i>	LECTURE 381 <i>C. Lebbé</i>
LECTURE 388 <i>A. Hauschild</i>	LECTURE 389 <i>C. Lebbé</i>	LECTURE 390 <i>C. Robert</i>	LECTURE 391 <i>J. Grob</i>	LECTURE 392 <i>A. Hauschild</i>	LECTURE 393 <i>C. Lebbé</i>
LECTURE 400 <i>A. Hauschild</i>	LECTURE 401 <i>C. Lebbé</i>	LECTURE 402 <i>C. Robert</i>	LECTURE 403 <i>J. Grob</i>	LECTURE 404 <i>A. Hauschild</i>	LECTURE 405 <i>C. Lebbé</i>
LECTURE 412 <i>A. Hauschild</i>	LECTURE 413 <i>C. Lebbé</i>	LECTURE 414 <i>C. Robert</i>	LECTURE 415 <i>J. Grob</i>	LECTURE 416 <i>A. Hauschild</i>	LECTURE 417 <i>C. Lebbé</i>
LECTURE 424 <i>A. Hauschild</i>	LECTURE 425 <i>C. Lebbé</i>	LECTURE 426 <i>C. Robert</i>	LECTURE 427 <i>J. Grob</i>	LECTURE 428 <i>A. Hauschild</i>	LECTURE 429 <i>C. Lebbé</i>
LECTURE 436 <i>A. Hauschild</i>	LECTURE 437 <i>C. Lebbé</i>	LECTURE 438 <i>C. Robert</i>	LECTURE 439 <i>J. Grob</i>	LECTURE 440 <i>A. Hauschild</i>	LECTURE 441 <i>C. Lebbé</i>
LECTURE 448 <i>A. Hauschild</i>	LECTURE 449 <i>C. Lebbé</i>	LECTURE 450 <i>C. Robert</i>	LECTURE 451 <i>J. Grob</i>	LECTURE 452 <i>A. Hauschild</i>	LECTURE 453 <i>C. Lebbé</i>
LECTURE 460 <i>A. Hauschild</i>	LECTURE 461 <i>C. Lebbé</i>	LECTURE 462 <i>C. Robert</i>	LECTURE 463 <i>J. Grob</i>	LECTURE 464 <i>A. Hauschild</i>	LECTURE 465 <i>C. Lebbé</i>
LECTURE 472 <i>A. Hauschild</i>	LECTURE 473 <i>C. Lebbé</i>	LECTURE 474 <i>C. Robert</i>	LECTURE 475 <i>J. Grob</i>	LECTURE 476 <i>A. Hauschild</i>	LECTURE 477 <i>C. Lebbé</i>

Program

Thursday, January 16th, 2014

13:45-14:00	PLENARY SESSION 1: Welcome and course introduction <i>Chairpersons: Claus Garbe and Sibel Alper</i>
14:00-14:30	LECTURE 1: Modern diagnostic tools for early detection of melanoma <i>Josep Malvehy, Barcelona, Spain</i>
14:30-15:00	LECTURE 2: Dermoscopic melanoma diagnosis <i>Sedef Şahin, Istanbul, Turkey</i>
15:00-15:30	Coffee Break
15:30-16:30	COURSE A: Oncogenetic diagnosis and mutational screening <i>Ketty Peris, L'Aquila, Italy</i>
15:30-16:30	COURSE B: Tumorbiopsy and sentinel node biopsy <i>Claus Garbe, Tuebingen, Germany</i>
15:30-16:30	COURSE C: Epithelial skin cancer: topical and medical treatments in early and advanced diseases <i>Alexander Stratigos, Athens, Greece</i>
15:30-16:30	COURSE D: Dermoscopy case presentations <i>Rana Yavuzer Anadolu, Ankara, Turkey</i>
16:30-17:00	Coffee Break
17:00-18:00	COURSE B: Tumorbiopsy and sentinel node biopsy <i>Claus Garbe, Tuebingen, Germany</i>
17:00-18:00	COURSE C: Epithelial skin cancer: topical and medical treatments in early and advanced diseases <i>Alexander Stratigos, Athens, Greece</i>
17:00-18:00	COURSE D: Dermoscopy case presentations <i>Rana Yavuzer Anadolu, Ankara, Turkey</i>
17:00-18:00	COURSE A: Oncogenetic diagnosis and mutational screening <i>Ketty Peris, L'Aquila, Italy</i>

Friday, January 17th, 2014

PLENARY SESSION 2

Chairpersons: Veronique del Marmol and Isabel Longo

08:00-08:30	LECTURE 3: Nevus screening and early detection of melanoma <i>Veronique del Marmol, Brussels, Belgium</i>
08:30-09:00	LECTURE 4: The current AJCC classification of skin tumors <i>Isabel Longo, Madrid, Spain</i>
09:00-09:30	LECTURE 5: Serologic and imaging diagnostics for tumor staging <i>Claus Garbe, Tuebingen, Germany</i>
09:30-10:00	Coffee Break
10:00-11:00	COURSE C: Epithelial skin cancer: topical and medical treatments in early and advanced diseases <i>Alexander Stratigos, Athens, Greece</i>
10:00-11:00	COURSE D: Dermoscopy case presentations <i>Rana Yavuzer Anadolu, Ankara, Turkey</i>
10:00-11:00	COURSE A: Oncogenetic diagnosis and mutational screening <i>Ketty Peris, L'Aquila, Italy</i>
10:00-11:00	COURSE B: Tumorbiopsy and sentinel node biopsy <i>Claus Garbe, Tuebingen, Germany</i>
11:00-11:30	Coffee Break
11:30-12:30	COURSE D: Dermoscopy case presentations <i>Rana Yavuzer Anadolu, Ankara, Turkey</i>
11:30-12:30	COURSE A: Oncogenetic diagnosis and mutational screening <i>Ketty Peris, L'Aquila, Italy</i>
11:30-12:30	COURSE B: Tumorbiopsy and sentinel node biopsy <i>Claus Garbe, Tuebingen, Germany</i>
11:30-12:30	COURSE C: Epithelial skin cancer: topical and medical treatments in early and advanced diseases <i>Alexander Stratigos, Athens, Greece</i>

12:30-14:00 Lunch

PLENARY SESSION 3

Chairpersons: Hubert Pehamberger and Eggert Stockfleth

14:00-14:30 **LECTURE 6: Treatment algorithms in metastatic melanoma**
Hubert Pehamberger, Vienna, Austria

14:30-15:00 **LECTURE 7: Surveillance and management of immunosuppressed patients**
Eggert Stockfleth, Berlin, Germany

15:00-15:30 Coffee Break

15:30-16:30 COURSE E: **Skin cancer prevention**
Jean-Jacques Grob, Marseille, France

15:30-16:30 COURSE F: **Adjuvant treatment with classical and pegylated IFN-alpha**
Axel Hauschild, Kiel, Germany

15:30-16:30 COURSE G: **Vemurafenib and other tyrosine kinase inhibitors**
Celeste Lebbé, Paris, France

15:30-16:30 COURSE H: **Ipilimumab/PD1 antibodies**
Caroline Robert, Paris, France

16:30-17:00 Coffee Break

17:00-18:00 COURSE F: **Adjuvant treatment with classical and pegylated IFN-alpha**
Axel Hauschild, Kiel, Germany

17:00-18:00 COURSE G: **Vemurafenib and other tyrosine kinase inhibitors**
Celeste Lebbé, Paris, France

17:00-18:00 COURSE H: **Ipilimumab/PD1 antibodies**
Caroline Robert, Paris, France

17:00-18:00 COURSE E: **Skin cancer prevention**
Jean-Jacques Grob, Marseille, France

Saturday, January 18th, 2014

08:00-09:00 COURSE G: **Vemurafenib and other tyrosine kinase inhibitors**
Celeste Lebbé, Paris, France

08:00-09:00 COURSE H: **Ipilimumab/PD1 antibodies**
Caroline Robert, Paris, France

08:00-09:00 COURSE E: **Skin cancer prevention**
Jean-Jacques Grob, Marseille, France

08:00-09:00 COURSE F: **Adjuvant treatment with classical and pegylated IFN-alpha**
Axel Hauschild, Kiel, Germany

PLENARY SESSION 4

Chairpersons: Claus Garbe and Axel Hauschild

09:00-09:30 LECTURE 8: **Oncogenetics and epidemiology of advanced basal cell carcinoma**
Claus Garbe, Tuebingen, Germany

09:30-10:00 LECTURE 9: **New treatment options for advanced basal cell carcinoma**
Axel Hauschild, Kiel, Germany

10:00-10:15 Coffee Break

10:15-11:15 COURSE H: **Ipilimumab/PD1 antibodies**
Caroline Robert, Paris, France

10:15-11:15 COURSE E: **Skin cancer prevention**
Jean-Jacques Grob, Marseille, France

10:15-11:15 COURSE F: **Adjuvant treatment with classical and pegylated IFN-alpha**
Axel Hauschild, Kiel, Germany

10:15-11:15 COURSE G: **Vemurafenib and other tyrosine kinase inhibitors**
Celeste Lebbé, Paris, France

11:15-11:30 Coffee Break

PLENARY SESSION 5

Chairpersons: Reinhard Dummer and Jürgen Becker

11:30-12:00 LECTURE 10: **Rare cutaneous malignancies**
Judit Oláh, Szeged, Hungary

12:00-12:30 LECTURE 11: **Merkel cell carcinoma and dermatofibrosarcoma protuberans**
Jürgen Becker, Graz, Austria

12:30-13:00 LECTURE 12: **How to recognize cutaneous lymphomas**
Nilsel Ílter, Ankara, Turkey

13:00-13:30 LECTURE 13: **Cutaneous lymphoma treatment**
Reinhard Dummer, Zurich, Switzerland

13:30-14:30 Lunch (with lunch box)

EADO Dermato-Oncology Committee

Sibel Alper, Istanbul, Turkey

Claus Garbe, Tuebingen, Germany

Judit Oláh, Szeged, Hungary

Hubert Pehamberger, Vienna, Austria

Course Faculty

Sibel Alper, Istanbul, Turkey

Jürgen Becker, Graz, Austria

Veronique del Marmol, Brussels, Belgium

Reinhard Dummer, Zurich, Switzerland

Claus Garbe, Tuebingen, Germany

Jean-Jacques Grob, Marseille, France

Axel Hauschild, Kiel, Germany

Nilsel İter, Ankara, Turkey

Celeste Lebbé, Paris, France

Isabel Longo, Madrid, Spain

Josep Malvehy, Barcelona, Spain

Judit Oláh, Szeged, Hungary

Hubert Pehamberger, Vienna, Austria

Ketty Peris, L'Aquila, Italy

Caroline Robert, Paris, France

Sedef Şahin, Istanbul, Turkey

Eggert Stockfleth, Berlin, Germany

Alexander Stratigos, Athens, Greece

Rana Yavuzer Anadolu, Ankara, Turkey

General Information

Course Venue

Point Hotel Taksim
Topçu Caddesi No.2
34437 Taksim - Istanbul, Turkey
Phone: +90 212 313 5000
E-Mail: info@pointhotel.com
www.pointhotel.com/taksim/english/

Course Organization



MedConcept
Gesellschaft für medizinische Projekte mbH
Ms. Mirja Christ
August-Borsig-Ring 37
15566 Schöneiche b. Berlin, Germany
Phone: +49 (0) 30 64387420
Fax: +49 (0) 30 64387435
E-Mail: mirja.christ@medconcept.org; info@medconcept.org
www.medconcept.org

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Exhibition

A commercial exhibition will be held at the meeting venue, close to the main meeting rooms. If you are interested in participating as an exhibitor, please contact MedConcept's secretariat for further information.

Exhibition opening hours

Thursday, January 16: 13:00-18:30
Friday, January 17: 07:30-18:30
Saturday, January 18: 07:30-14:00

CME Credits

An application for CME accreditation will be made.

Cancellation Policy

Cancellations must be received in writing by December 17th, 2013. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to mirja.christ@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Registration Form

Second European School of Dermato-Oncology, organized by EADO: Fundamentals of Cutaneous Oncology

Istanbul, Turkey, January 16th-18th, 2014

First Name: _____ Last Name: _____

Professional Title: _____ Degree: MD PhD RN PA-C

Gender: Male Female Speciality: _____

Institution: _____ Address: _____

City: _____ Zip Code: _____ Country: _____

Daytime Telephone: _____ Fax: _____ E-Mail: _____

Fees

Registration Fee of **380,00 Euro** (incl. VAT) covers

- Admission to scientific sessions
- Admission to exhibition
- Bag with course documents
- Welcome reception
- Coffee breaks and lunch

Payment Method

Bank Transfer:

Credit Card: MasterCard Visa American Express

Credit Card Number: _____

Expiration Date: _____

Security Code CCV: _____ (MC/Visa - 3 digits on back, AMEX - 4 digits on front)

Cardholder Name: _____

Signature: _____

An invoice will be sent by mail to the given address. If the invoice address is different from the address given above, please send an email including the name of the registrant and the full invoice address to mirja.christ@medconcept.org.

To Register

Mail registration form to:

MedConcept GmbH

August-Borsig-Ring 37

15566 Schöneiche bei Berlin, Germany

Fax registration form to: +49 30 64387435

Register online: www.dermato-oncology2014.org

